An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The peptide-based vaccine induces a t cell-dependent response
Both companies have been selected for stand-by production by German government
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Subscribe To Our Newsletter & Stay Updated
